Author

A. S. Azmi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:mouse· 3 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

A. Aboukameel· 4 shared H. Y. Khan· 4 shared M. H. Uddin· 4 shared S. Kim· 4 shared M. N. Al-Hallak· 3 shared R. Beydoun· 3 shared S. Bannoura· 3 shared Y. Mzannar· 3 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Aboukameel

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis

S. F. Bannoura, A. Aboukameel, H. Y. Khan, M. H. Uddin, H. Jang, E. Beal, A. Thangasamy, S. Kim, K.-U. Wagner, R. Mohammad, M. N. Al Hallak, B. Pasche, A. S. Azmi

This study identifies RCC1 as a novel therapeutic target in PDAC, showing its role in tumor progression and drug resistance through the c-Myc-RCC1-Ran axis.

bioRxiv · Dec 18, 2023 · PreprintCancer Biology

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers

H. Y. Khan, M. Nagasaka, A. Aboukameel, O. Alkhalili, M. H. Uddin, S. Bannoura, Y. Mzannar, A. Ibrahim, E. Beal, M. Tobon, S. Kim, R. Beydoun, E. Baloglu, W. Senapedis, B. Elrayes, , A. S. Azmi

This study shows that combining KRASG12C inhibitors with PAK4 inhibitor KPT9274 enhances antitumor activity and survival in preclinical models of KRASG12C mutant pancreatic and lung cancers.

bioRxiv · Mar 27, 2023Cancer Biology

Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer model

M. H. Uddin, A. Aboukameel, Y. Li, H. Y. Khan, R. E. Sexton, S. Bannoura, G. Dyson, M. N. Al-Hallak, Y. Mzannar, A. Mohamed, Y. Landesman, S. Kim, R. Beydoun, R. M. Mohammad, A. F. Shields, A. S. Azmi

This study investigates the synergy between XPO1 inhibitor selinexor and gemcitabine-nab-paclitaxel in pancreatic cancer using cellular and mouse models, showing improved survival and molecular changes.

bioRxiv · Mar 8, 2022 · PreprintCancer Biology

Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancers

H. Y. Khan, M. Nagasaka, Y. Li, A. Aboukameel, M. H. Uddin, R. Sexton, S. Bannoura, Y. Mzannar, M. N. Al-Hallak, S. Kim, R. Beydoun, Y. Landesman, H. Mamdani, D. Uprety, P. A. Philip, , A. S. Azmi

This paper shows that combining XPO1 inhibitor selinexor with KRAS G12C inhibitors enhances antitumor effects in preclinical models of KRAS G12C mutant cancers.

bioRxiv · Jan 26, 2022Cancer Biology